"Global IND Filing for SOT106 Planned for the Second Half of 2026"

Rigakembio Science announced on the 9th that it is scheduled to receive a development milestone payment under the ADC platform technology transfer agreement signed with Sotio Biotech.

Rigakembaio logo image. Rigakembaio

Rigakembaio logo image. Rigakembaio

View original image

This milestone is based on the development progress of SOT106, an LRRC15-targeted ADC candidate that is being developed to treat sarcoma and LRRC15-positive solid tumors. Sotio plans to submit an Investigational New Drug (IND) application in the second half of 2026 to initiate a global clinical trial.


Rigakembio signed a multi-target ADC platform technology transfer agreement with Sotio in November 2021. Sotio is conducting research and development of candidate substances by applying Rigakembio's ADC platform ConjuAll to its own antibodies. Under this agreement, Rigakembio secured the right to receive up to 1.0275 billion dollars (approximately 1.5034 trillion won) in milestone payments linked to development and regulatory achievements, as well as sales-based royalties. Sotio is responsible for research and development, manufacturing, and commercialization.



SOT106 targets LRRC15, which is expressed in sarcoma and other solid tumors with high unmet medical needs. Sotio presented preclinical study results at the American Association for Cancer Research (AACR) in 2025. In mouse models of soft tissue sarcoma and osteosarcoma, SOT106 demonstrated superior anticancer efficacy compared to a control agent using the same MMAE payload. Sotio explained that complete remission was observed at a dose of 1 mg/kg.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing